Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.

Halda, Accent and Vividion take more projects into phase 1.

But investors remain unimpressed with the Nectin-4 ADC Corbus bought for just $7.5m.

Opdualag chalks up another failure, this time in the extension of an approved use.

Phase 1 data give investors a benchmark for mevrometostat's pivotal Mevpro-1 trial.

But the overall survival benefit in prostate cancer is still driven by HRR mutations.